Aman's Global Market Intelligence

1 · Executive dashboard

Risk-on, fragile

Regime call: Friday's record S&P close, technology leadership, positive breadth, falling Treasury yields and VIX 14.90 support a risk-on label. The label is deliberately qualified: July payrolls fell 23,000, the coming CPI/PPI sequence can reprice rates, and oil remains exposed to U.S.–Iran headlines. The evidence favors selective participation, not indiscriminate chasing.

S&P 5007,757.64+0.62% Fri · +3.58% wk

Nasdaq Composite26,690.62+1.30% Fri · +5.19% wk

Dow Jones54,036.93+0.28% Fri · +2.96% wk

Russell 20003,034.49+1.10% Fri · +3.52% wk

VIX · Cboe14.90−1.65% Fri · −6.82% wk

U.S. 2Y · Treasury4.19%−6 bp Fri

U.S. 10Y · Treasury4.65%−4 bp Fri

DXY proxy99.60−0.20% wk

WTI Sep proxy$78.18−7.67% wk

Gold Dec proxy$4,340.70+7.20% wk

Global market	Aug. 7 close	Week	Signal into Monday
Nikkei 225	65,606.71	+1.93%	Positive but volatile
Hang Seng	25,668.03	−0.84%	Regional laggard
Shanghai Composite	3,940.04	+2.81%	Mainland strength
Kospi	6,258.77	−5.10%	Sharp divergence; risk flag
STOXX Europe 600	660.25	+1.70%	Fourth straight record Friday
Euro STOXX 50	6,523.86	+2.61%	Large-cap leadership
DAX	26,319.45	+2.69%	Near record territory
FTSE 100	10,901.10	+0.30%	European laggard

1 · Inflation is the week's gate

Confirmed: BLS schedules July CPI for Aug. 12 and PPI for Aug. 13, both 08:30 ET. Inference: benign readings would reinforce the post-jobs duration rally; upside surprises would challenge record equity multiples and the 4.65% 10Y.

2 · AI demand gets three tests

CoreWeave reports Aug. 11, Cisco Aug. 12 and Applied Materials Aug. 13. Together they test financed AI-cloud growth, networking orders, semiconductor equipment demand and export exposure before NVIDIA's Aug. 26 report.

3 · Risk price is low

Cboe's official Friday VIX close was 14.90 even as labor weakened and geopolitical oil risk persists. Low implied volatility confirms calm—not safety—and creates asymmetry if CPI or oil surprises.

2 · Market drivers & coming-week risk map

Facts separated from inference

Confirmed macro / liquidity

BLS reported July payrolls of −23,000, unemployment 4.1%, labor participation 61.4% and wage growth 3.2% y/y; May–June were revised down by a combined 103,000.
Official Treasury Aug. 7 curve: 2Y 4.19%, 10Y 4.65%; the curve remains positively sloped by 46 bp.
The Federal Reserve's July 28–29 meeting is complete; the Fed states regular-meeting minutes are released three weeks after the decision, placing the next minutes on Aug. 19.
Friday's S&P, Nasdaq and Dow gains capped their strongest percentage week since April; Friday NYSE/Nasdaq breadth was positive in the prior Reuters cross-check.

Inference / positioning use

Goldilocks test: weaker labor plus softer inflation is favorable for duration. Weaker labor plus sticky inflation is stagflationary and would hit both earnings confidence and multiples.
Curve signal: lower front-end yields imply less tightening pressure, but a 10Y near 4.65% is not an easy discount-rate backdrop for long-duration speculative equities.
Leadership quality: semiconductor/software outperformance and broad Friday participation are constructive; the record tape becomes less trustworthy if breadth narrows after CPI.
Cash is a position: with no Sunday futures signal and three high-impact releases/events midweek, Monday gap-chasing offers an inferior evidence set.

Macro risk High

Trigger: CPI/PPI above consensus, especially sticky services/core. Transmission: 10Y >4.70%, lower long-duration multiples, pressure on speculative quantum and unprofitable AI cloud. Offset: downside inflation surprise with stable breadth.

Geopolitical / oil High

Confirmed context: recent U.S.–Iran diplomacy helped oil fall, but Reuters described no signed framework and constrained physical flows. Risk: renewed strikes or shipping disruption reverses the inflation relief. Treat weekend headlines as non-price-confirmed until futures reopen.

Earnings / financing Medium-high

Trigger: CRWV, CSCO and AMAT guidance. Positive: durable orders, utilization and margins. Negative: capex funded by leverage without improving unit economics, export restrictions, customer concentration or slowing orders.

3 · Thematic dashboards

AI infrastructure Leadership

Performance: SMH +7.80%, IGV +8.57%, NVDA +11.56% last week.
Stack: compute/networking leaders remain strongest; cooling/power and data-center construction continue to matter, but order quality and return on capex are now as important as headline spend.
Verified catalysts: CRWV Aug. 11; CSCO Aug. 12; AMAT Aug. 13; NVIDIA Aug. 26 at 14:00 PT.
Risk: record indices, export rules, customer concentration, power/packaging constraints and execution expectations. Do not infer sector-wide upside from one supplier's AI wording.

Quantum computing Economics lag price

Performance: IONQ +21.93% and RGTI +20.00% last week; momentum is strong after earnings.
IONQ primary facts: Q2 revenue $80.05M (+287% y/y), 2026 guide to $290M high end, but Q2 adjusted EBITDA was −$120.3M and six-month operating cash use $254.8M.
RGTI primary facts: Q2 revenue $5.14M versus $28.06M operating loss; $541.3M cash/investments and no conventional debt provide runway.
Risk: roadmap claims, government awards and cash do not by themselves validate valuation. Require recurring commercial conversion and narrowing loss intensity.

Peptide / metabolic biotech Demand; valuation risk

Performance: XBI +7.05%, XLV +1.93%, LLY +3.21%, VKTX +7.94% last week.
Leader: Lilly's previously primary-source-verified Q2 revenue rose 48%; Mounjaro +91% and Zepbound +46%.
Competition: Novo, Amgen, Zealand/Boehringer and Viking keep efficacy, tolerability, oral delivery and manufacturing central.
Biotech discipline: VKTX remains high-risk: Phase 3 execution, safety/tolerability, cash runway, manufacturing, dilution and binary data matter more than thematic enthusiasm.

4 · Ranked ideas for the coming week

Conditional setups; fewer is better

#1 NVDA · NVIDIA Bullish / confirmation

Nasdaq · approx. $5.4T mega-cap · AI compute/networking · high valuation/event risk

Current-session: no Sunday trade1–4 week swing: applicable after CPI3–12+ month investment: applicable

Thesis / uncertain direction: may continue to lead if CPI is benign and this week's AI-infrastructure earnings validate orders and capex quality.

Catalyst / evidence: CRWV/CSCO/AMAT read-through, then company-confirmed Aug. 26 results; $223.96 Friday close after +11.56% week.

Counterargument: strong momentum embeds demanding expectations; export, customer concentration, supply/power and hyperscaler-return risks persist.

Technical / fundamental context: Friday high $224.76 and low $220.66; close near the high confirms relative strength but also chase risk.

Entry / confirmation: after CPI, require hold above $220.66 with stable/falling 10Y, or high-volume close above $224.76.

Invalidation / downside: close below $217, 10Y decisively above 4.70%, or weaker demand/guidance. A pre-earnings gap toward prior consolidation is plausible.

Principal risks: inflation/yields, earnings gap, regulation, export controls, concentration, capex digestion.

Confidence

Risk

Opportunity

Confidence: strong price/demand/catalyst evidence, macro-dependent. Risk: valuation and event concentration. Opportunity: verified leadership, but reduced one point for chase risk.

#2 LLY · Eli Lilly Bullish long-term / patience

NYSE · approx. $1.1T mega-cap · peptide/metabolic therapeutics · policy, competition and valuation risk

Current-session: no edge1–4 week: confirmation needed3–12+ month: applicable on disciplined entry

Thesis / uncertain direction: verified incretin growth may support long-run compounding; failed Friday support means near-term direction is less clear.

Catalyst / evidence: Q2 revenue +48%; Mounjaro +91%, Zepbound +46%; pipeline, prescription and manufacturing updates.

Counterargument: premium valuation, competing oral/injectable programs, pricing/reimbursement, safety and manufacturing could outweigh growth.

Context: $1,185.71 close; Friday range $1,161.20–$1,196.80; +3.21% week but volatile post-earnings tape.

Entry / confirmation: require close above $1,196.80 or a multi-session base above $1,161.20; do not average blindly.

Invalidation / downside: sustained break below $1,161 with estimate cuts; demand, safety, reimbursement or manufacturing deterioration. Premium multiple compression can be material.

Principal risks: policy/pricing, competition, manufacturing, safety, litigation and concentration in incretins.

Confidence

Risk

Opportunity

#3 RGTI · Rigetti Avoid chasing · not a short

Nasdaq · approx. $6B speculative small/mid-cap · quantum · very high volatility/dilution/squeeze risk

Current-session: avoid1–4 week: no actionable short3–12+ month: milestone watch only

Thesis / uncertain direction: Q2 economics do not support chasing +20% weekly momentum; prior bearish timing failed, so no short trigger is asserted.

Catalyst / evidence: Q2 $5.14M revenue, $2.19M gross profit and $28.06M operating loss; large liquidity balance supports operations but not valuation.

Counterargument: $541.3M liquidity, no conventional debt, deployments, U.S. government support and roadmap progress can sustain a strategic premium.

Context: $17.94 Friday close near $17.95 high on heavy volume; momentum and squeeze risk are explicit.

Confirmation: reconsider long only after funded awards plus recurring commercial conversion; bearish setup requires failed breakout and close below $16.40.

Invalidation / downside: avoid view weakens on large recurring wins and independently verified technical scale. Long downside is multiple collapse/dilution.

Principal risks: volatility, technical claims, dilution, government funding conditions; no borrow availability or fee asserted.

Confidence

Risk

Opportunity

#4 IONQ · IonQ Avoid at price · not a short

NYSE · approx. $16B speculative mid-cap · quantum · high loss/M&A/dilution risk

Current-session: avoid volatility1–4 week: no edge3–12+ month: watch conversion

Thesis / uncertain direction: growth is real but +21.93% weekly momentum and loss intensity create poor risk/reward without proof of operating leverage.

Catalyst / evidence: Q2 $80.05M revenue (+287% y/y), raised guide; adjusted EBITDA −$120.3M and operating cash use $254.8M for six months.

Counterargument: $1.24B quarter-end cash/restricted cash, international/commercial mix and rapid revenue growth may support strategic value.

Context: $44.43 close; Friday range $40.00–$44.62 and +11.86%; momentum invalidated the earlier avoid timing.

Confirmation: require narrowing cash burn/loss intensity and durable gross-margin improvement, or a valuation reset.

Invalidation / downside: avoid view changes on verified margin inflection and recurring conversion. Downside includes acquisition integration, dilution and multiple compression.

Principal risks: technology roadmap, procurement timing, warrants, M&A and squeeze risk; no borrow terms asserted.

Confidence

Risk

Opportunity

Watchlist — confirmation needed

CSCO · Cisco Watch

Nasdaq · mega-cap · AI/data-center networking · moderate risk

Horizon: 1–4 week / investment only after Aug. 12 results. Thesis: AI networking/orders may improve mix. Confirm: order growth, margins and guidance—not AI mentions alone. Counter/downside: weak enterprise orders, competition or guide can gap shares. Scores C/R/O: 67/64/66.

AMAT · Applied Materials Watch

Nasdaq · mega-cap · semiconductor equipment/AI enabler · cycle/export risk

Horizon: 1–4 week after company-confirmed Aug. 13 call. Thesis: advanced-node, memory and packaging spend may support demand. Confirm: orders/guidance and high-volume hold. Counter/downside: China/export restrictions and capex cyclicality. Scores C/R/O: 69/68/67.

CRWV · CoreWeave High-risk watch

Nasdaq · large-cap, high leverage/concentration risk · AI cloud

Horizon: no pre-earnings trade; assess Aug. 11. Confirm: backlog conversion, utilization, cash generation and financing. Counter/downside: customer concentration, debt/capex and price competition can overwhelm revenue growth. Scores C/R/O: 55/86/61.

VKTX · Viking Therapeutics Speculative biotech

Nasdaq · mid-cap biotech · metabolic/peptide platform · binary/dilution risk

Horizon: milestone watch, not current-session trade. Confirm: statistically robust Phase 3 execution, tolerability and cash/manufacturing clarity. Counter/downside: crowded market, trial delay/failure, safety, dilution and reimbursement. Scores C/R/O: 54/88/58.

5 · Changes since the Aug. 8 report

No new cash session: prices, technical levels and regime are unchanged because markets remained closed; no weekend indication is promoted to evidence.
NVDA: retained #1, but Opportunity 76→75 and Risk 63→64 to reflect chase risk before CPI and a +11.56% week.
RGTI / IONQ: evidence confidence raised one to three points after direct primary-source reconciliation of Q2 statements; classification remains avoid-chasing/not-short because business evidence does not resolve price direction.
Calendar tightened: BLS directly confirms CPI Aug. 12 and PPI Aug. 13. A third-party calendar result incorrectly grouped releases on Aug. 10 and was rejected.
No additions/removals: LLY remains the long-horizon peptide leader; CSCO, AMAT, CRWV and VKTX remain watch-only.

6 · Important 7–30 day catalysts

Times ET unless noted

Aug. 10 · Monday — U.S. cash session reopens

No major BLS inflation release; watch whether Friday's breadth persists and whether oil/futures validate weekend news.

Aug. 11 · 17:00 — CoreWeave Q2 results

AI-cloud demand, backlog quality, utilization, capex financing and customer concentration.

Aug. 12 · 08:30 — July CPI and real earnings

BLS-confirmed. Primary cross-asset gate; assess core services, shelter and revisions rather than headline alone.

Aug. 12 · after close — Cisco Q4 FY26

AI networking orders, enterprise demand, margins and forward guidance. Company IR link in sources.

Aug. 13 · 08:30 — July PPI

BLS-confirmed. Pipeline inflation and potential PCE read-through.

Aug. 13 · 16:30 — Applied Materials Q3 call

Company-confirmed. Foundry/logic, memory, advanced packaging, China/export commentary.

Aug. 14 · 08:30 — July retail sales

Consumption test after weak payrolls; verify consensus near release.

Aug. 19 · 14:00 — FOMC minutes

Timing follows the Fed's three-week release convention after Jul. 29. Watch division over further tightening.

Aug. 19 — IonQ conference appearance

Focus on recurring revenue conversion, cash burn and integration—not promotional roadmap language.

Aug. 26 · 14:00 PT — NVIDIA Q2 FY27 results

Company-confirmed. Data-center growth, supply, networking, margins, export effects and forward demand.

7 · Bottom line

Current-session / day trade

No Sunday trade; no Monday precommitment. The best evidence-based tactic is to wait for liquid futures/cash confirmation. A Friday-high breakout without breadth or with a rising 10Y is not enough.

1–4 week swing

NVDA on confirmation. Require post-CPI stability above $220.66 or a high-volume close above $224.76 with the 10Y contained. Biggest risk: hot inflation or weak AI-capex read-through.

3–12+ month investment

LLY on disciplined pullbacks. The strongest evidence is verified operating momentum. The view changes with demand/estimate deterioration, safety, reimbursement, competition or manufacturing problems.

Regime invalidation: downgrade toward neutral/risk-off if CPI/PPI surprise higher, the 10Y closes decisively above 4.70%, oil jumps on renewed conflict, or breadth contracts while indices make new highs. Upgrade conviction only if inflation is benign, yields remain stable/fall and breadth persists through the earnings tests. Biggest risk: the market is pricing rate relief from weak labor while VIX is low; a stagflationary surprise attacks both earnings and valuation.

Sources & data quality

Data-quality panel

Latest price session is Friday Aug. 7. U.S. index closes were cross-checked between CNBC's live quote page and CNBC's market-close report; Cboe's downloadable history directly confirms VIX 14.90.
Official Treasury XML directly confirms Aug. 7 2Y 4.19% and 10Y 4.65%. Friday close convention can differ slightly from late electronic trading quotes.
Asian/European closes, DXY, WTI and gold are carried from the Aug. 8 report's Friday-close cross-check; they are not executable weekend prices. Futures were unavailable because regulated sessions were closed.
Yahoo chart API returned HTTP 429 in this run. CNBC/browser quotes, Cboe and Treasury succeeded, so no unavailable-data declaration was necessary. Market-cap figures are approximate and especially unstable for quantum names.
Primary company releases were used for IonQ, Rigetti, Applied Materials and NVIDIA catalysts. Company forward-looking claims are treated as claims, not independently proven outcomes.
The initial two-week paper-tracking phase continues. Only one completed cash session of call history exists; no statistically meaningful hit rate is claimed.